Initiation of clinical imaging study

Annexin Pharmaceuticals and Collaborators Initiate a Clinical Study in Patients with Retinal Vein Occlusion (RVO) Using Fluorescent Labelled ANXV. STOCKHOLM, SWEDEN (September 29, 2021) – Annexin Pharmaceuticals A...

Annexin Pharmaceuticals prepares RVO study in the US

Annexin Pharmaceuticals has decided to carry out its phase 2/proof of concept study in RVO in the US. The US is the largest market for RVO, and leading experts in the field can thereby participate in the...

Regulatory authorities confirm Annexin’s plans in RVO

Annexin Pharmaceuticals has conducted successful meetings with regulatory authorities in the United States and Europe. The authorities have confirmed the company’s plans for development of the drug candidate A...
Back to top